Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PI3K pathway activation occurs in concomitance with RAS/BRAF mutations in colorectal cancer, limiting the sensitivity to targeted therapies.
|
26272063 |
2015 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A flow-cytometry-based apoptosis detection kit was used to determine PI3K inhibitor-induced apoptosis in CRC cell lines SW480 and SW620.
|
22851869 |
2012 |
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A known target of CK2 is Akt, a player in the PI3K/Akt/mTORC1 signaling pathway, which is aberrantly activated in 32% of colorectal cancer (CRC) patients.
|
30683840 |
2019 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Activation of phosphatidylinositol 3-kinase (PI3K)/Akt signaling is associated with tumorigenesis and metastasis of colorectal cancer (CRC).
|
22696593 |
2012 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although AKT activity was elevated in KRAS mutant cells, and PI3K inhibition did impair the growth of MEK inhibitor-insensitive CRC cell lines, concurrent treatment with selumetinib did not provide additional antitumor activity.
|
21199803 |
2011 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anthocyanins Prevent and Inhibit Colorectal Cancer through PI3K/AKT/survivin Signaling Pathway.
|
31830892 |
2019 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.
|
23826249 |
2013 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Arginine ADP-ribosyltransferase 1 promotes angiogenesis in colorectal cancer via the PI3K/Akt pathway.
|
26847718 |
2016 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Assessment of PI3K/AKT/PTEN signaling pathway activity in colorectal cancer using quantum dot-conjugated antibodies.
|
29422975 |
2018 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on the above‑mentioned results, the dual PI3K/mTOR and ATP‑competitive mTOR inhibitors have demonstrated high potential for targeting the mTOR pathway in CRC.
|
29845289 |
2018 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Brahma-related gene-1 has an important role in the process of CRC development by activating the PI3K-Akt signalling pathway and resultant upregulation of cyclin D1 levels.
|
21102582 |
2011 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bromodomain-containing protein 4 (BRD4) and phosphatidylinositol 3-kinase (PI3K) are key oncogenic cascades in colorectal cancer (CRC).
|
30933440 |
2019 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CCR7 high expression leads to cetuximab resistance by cross-talking with EGFR pathway in PI3K/AKT signals in colorectal cancer.
|
31815051 |
2019 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, we conclude that overexpression of CHRNA7 negatively controls colorectal cancer LoVo cell invasion and metastasis via PI3K/Akt pathway activation and may serve as either a diagnostic marker or a therapeutic target for colorectal cancer metastasis.
|
26719016 |
2016 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, we show that P. anaerobius drives CRC via a PCWBR2-integrin α<sub>2</sub>/β<sub>1</sub>-PI3K-Akt-NF-κB signalling axis and identify the PCWBR2-integrin α<sub>2</sub>/β<sub>1</sub> axis as a potential therapeutic target for CRC.
|
31501538 |
2019 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CONCLUSIONS CLCA4 inhibits migration and invasion by suppressing EMT via PI3K/ATK signaling and predicts favorable prognosis of CRC which may help to distinguish potential risk of lymph node metastasis in CRC.
|
31164625 |
2019 |
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CONCLUSIONS OPN promoted cell proliferation, migration, and invasion, and was accompanied by upregulation of ALDH1-positive CSC in CRC through activation of PI3K-Akt-GSK/3ß-ß/catenin pathway.
|
31017126 |
2019 |
Colorectal Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cotreatment with GSK3β inhibitors may be a strategy to overcome the resistance of PIK3CA- and TCF7-mutant CRC to PI3K/mTOR-targeted therapies.
|
29978469 |
2019 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Crocin synergistically enhances the antiproliferative activity of 5-flurouracil through Wnt/PI3K pathway in a mouse model of colitis-associated colorectal cancer.
|
30129057 |
2018 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cudraflavone C Induces Tumor-Specific Apoptosis in Colorectal Cancer Cells through Inhibition of the Phosphoinositide 3-Kinase (PI3K)-AKT Pathway.
|
28107519 |
2017 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
DCLK1 promotes epithelial-mesenchymal transition via the PI3K/Akt/NF-κB pathway in colorectal cancer.
|
29277893 |
2018 |
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
DJ-1 expression was positively associated with PI3K-p110α, p-AKT, and HIF-1α expression in CRC.
|
30410397 |
2018 |
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Downregulation of KIAA0125 may contribute to CRC development via sponging of hsa-miR-29b-3p to regulate BCL2 expression or regulating the PI3K-Akt signaling pathway.
|
31043791 |
2019 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation.
|
26955235 |
2016 |
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dysregulation of the phosphoinositide 3-kinase (PI3K) and Src signaling pathways commonly occur in colorectal cancer.
|
22553375 |
2012 |